Nucleic Acid Therapies
March 24 - 26, 2021 Virtual
Abstract Deadline: January 15, 2021
Organizers:
Shalini Andersson, AstraZeneca
Masad Damha, McGill University
Anastasia Khvorova, University of Massachusetts Medical School
Matthew Stanton, Generation Bio
The seventh Cold Spring Harbor Laboratory meeting on Nucleic Acid Therapies is going fully virtual and will begin late morning EST on Wednesday, March 24, and will conclude late afternoon EST on Friday, March 26, 2021.
| Day | Time (EST) | Session # | Session Name |
| Wednesday |
9:30 am - 12:30 pm |
1 |
Nucleic Acid Chemistry |
| Wednesday |
1:00 pm - 2:00 pm |
|
Poster Session* |
| Wednesday |
2:30 pm - 5:30 pm |
2 |
Delivery |
| Thursday |
9:30 am - 12:30 pm |
3 |
Gene Editing |
| Thursday |
2:30 pm - 3:30 pm |
|
Keynote Presentation and Fireside Chat: Philip Dormitzer |
| Thursday |
4:00 pm - 5:00 pm |
|
Poster Session* |
| Friday |
9:30 pm- 12:30 pm |
4 |
Nucleic Acid Preclinical Programs |
| Friday |
1:00 pm - 2:00 pm |
|
Poster Session* |
| Friday |
2:30 pm - 5:30 pm |
5 |
Nucleic Acid Clinical Programs |
|
|
|
|
| Virtual Icebreaker |
Wednesday, 5:30 pm |
|
|
| Discussion Zone |
|
|
30-minutes following each oral session (open Zoom format) |
*Virtual Poster Session will be available for viewing throughout the meeting
Topics:
- Nucleic Acid Chemistry (Chairs Masad J. Damha and Muthiah Manoharan)
- Delivery (Chairs Steven Dowdy and Matthew Stanton)
- Gene Editing (Chairs Matthew Stanton and Laura Sepp-Lorenzino)
- Nucleic Acid Preclinical Programs (Chairs Annemieke Aartsma-Rus and Shalini Andersson)
- Nucleic Acid Clinical Programs (Chair Anastasia Khvorova)
Keynote Speaker:
Philip Dormitzer, Pfizer Pharmaceutical Company
Invited Speakers:
Oxana Beskrovnaya, Dyne Therapeutics
Annabelle Biscans, AstraZeneca, Sweden
Don Cleveland, University of California, San Diego
Michael Czech, University of Massachusetts Medical Center
James Dahlman, Georgia Tech
Christian Dombrowski, Intellia Therapeutics
Steven Dowdy, University of California, San Diego
Aurelie Goyenvalle, French Institute of Health & Medical Research, France
Alejandro (Alex) Garanto Iglesias, Radboud University Medical Center, The Netherlands
Shuling Guo, Ionis Pharmaceuticals, Inc.
T. Scott Johnson, Commanche Biopharma
Eric Kool, Stanford University
Art Levin, Avidity Biosciences LLC
Muthiah Manoharan, Alnylam Pharmaceuticals
Cosmin Mihai, Moderna Therapeutics
Andrew Scharenberg, University of Washington
Samuel Sternberg, Columbia University
Fyodor Urnov, Innovative Genomics Institute
Chandra Vargeese, Wave Life Sciences
Kate Zhang, Editas Medicine
Abstracts are welcomed on all scientific topics related to the development of RNA and other oligonucleotide-based therapeutic approaches. They should contain only new and unpublished material and must be submitted electronically by the abstract deadline. Selection of material for oral and poster presentation will be made by the organizers and individual session chairs. The status (talk/poster) of abstracts will be posted on our web site as soon as decisions have been made by the organizers.
We are eager to have as many young people as possible to attend since they are likely to benefit most from this meeting. We have applied for funds from industry to partially support graduate students and postdocs. Please apply in writing via email to Val Pakaluk and state your financial needs. Preference will be given to those submitting abstracts.
Meeting sponsored by:
Late Pricing: (registrations submitted after 5:00 p.m. EST on Thursday, March 18)
Virtual Late Package: $355
Virtual Late Graduate/PhD Student Package: $250
Virtual Late Corporate Package: $575
Social Media 
The designated hashtag for this meeting is #cshlNAT. Note that you must obtain permission from an individual presenter before live-tweeting or discussing his/her talk, poster, or research results on social media. Click the Policies tab above to see our full Confidentiality & Reporting Policy.